Screener
Exelixis EXEL R&D
R&D at other companies
Other financials
Where this comes from
Reported directly by Exelixis in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Exelixis’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:13 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q3 2026
- Accession
- 0000939767-26-000098
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total revenues | 628,690 | 568,261 | 1,239,502 | 1,123,708 |
| Operating expenses: | ||||
| Cost of goods sold | 20,657 | 19,470 | 40,610 | 38,642 |
| Research and development | 211,987 | 200,356 | 411,903 | 412,589 |
| Selling, general and administrative | 147,632 | 134,859 | 287,234 | 272,042 |
| Total operating expenses | 380,276 | 354,685 | 739,747 | 723,273 |
| Income from operations | 248,414 | 213,576 | 499,755 | 400,435 |
| Interest income | 14,210 | 16,789 | 30,337 | 35,865 |
Item 1. Financial Statements.
FAQ
- What is Exelixis's R&D?
- Exelixis (EXEL) reported R&D of $211.99M in Q2 2026.
- How has Exelixis's R&D changed year-over-year?
- Exelixis's R&D increased by 5.8% year-over-year, from $200.36M to $211.99M.
- What is the long-term trend for Exelixis's R&D?
- Over 4 years (2021 to 2025), Exelixis's R&D has grown at a 4.4% compound annual growth rate (CAGR), from $693.72M to $825M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Exelixis's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude